8-hydroxy-6H-[1,3]dioxolo[4,5-g]chromen-6-one | 14991-61-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 8-hydroxy-6H-[1,3]dioxolo[4,5-g]chromen-6-one
• 英文别名: 8-Hydroxy-[1,3]dioxolo[4,5-g]chromen-6-one
• CAS: 14991-61-8
• 化学式: C₁₀H₆O₅
• 分子量: 206.155
• InChiKey: XZKIXWJNPQREOM-UHFFFAOYSA-N

物化性质

• 沸点：
  428.6±45.0 °C(Predicted)
• 密度：
  1.672±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  8-hydroxy-6H-[1,3]dioxolo[4,5-g]chromen-6-one 在 三氯氧磷 作用下， 反应 6.0h， 以55%的产率得到8-chloro-6H-1,3-dioxolo[4,5-g][1]benzopyran-6-one
  参考文献：
  名称：

  Soman, Shubhangi S.; Trivedi, K. N., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1993, vol. 32, # 3, p. 372 - 373

  摘要：

  DOI：
• 作为产物：
  描述：

  1,3-苯并二氧戊环-5-基乙酸酯 在 三氟化硼乙醚 、 sodium hydride 、 溶剂黄146 作用下， 反应 5.5h， 生成 8-hydroxy-6H-[1,3]dioxolo[4,5-g]chromen-6-one
  参考文献：
  名称：

  EP3848367

  摘要：

  公开号：

文献信息

• A functional and self-assembling octyl-phosphonium-tagged esculetin as an effective siRNA delivery agent
  作者：Altab Shaikh、Praveen Kumar Neeli、Gajalakshmi Singuru、Sravya Panangipalli、Rajkumar Banerjee、Sridhar Reddy Maddi、Rajamannar Thennati、Surendar Reddy Bathula、Srigiridhar Kotamraju

  DOI：10.1039/d1cc03497a

  日期：——

  Herein, we describe the self-assembling ability of an amphiphilic phosphonium cationic lipid to form nanoparticles and deliver MnSOD siRNA into MDA-MB-231 cells.

  在这里，我们描述了一种两性磷酸铵阳离子脂质的自组装能力，以形成纳米颗粒并将MnSOD siRNA输送到MDA-MB-231细胞中。
• 色酮并喹啉杂环化合物的制备方法
  申请人：苏州大学

  公开号：CN109942587B

  公开（公告）日：2020-04-03

  本发明公开了由氨茴内酐和4‑羟基香豆素加热反应制备色酮并喹啉杂环的方法，反应包括以下步骤：把氨茴内酐和取代的4‑羟基香豆素溶于溶剂中，反应混合物在150℃～300℃反应0.2～5小时；停止加热，冷至室温，加水，用溶剂萃取，蒸干，柱层析纯化，得到产物色酮并喹啉杂环化合物。本发明是一种热促条件下氨茴内酐和4‑羟基香豆素的反应，这类转化不需要催化剂和添加物，副产物也少，是一种快速构建色酮并喹啉杂环化合物的新颖方法。
• Combining Silver Catalysis and Organocatalysis: A Sequential Michael Addition/Hydroalkoxylation One-Pot Approach to Annulated Coumarins
  作者：Daniel Hack、Pankaj Chauhan、Kristina Deckers、Gary N. Hermann、Lucas Mertens、Gerhard Raabe、Dieter Enders

  DOI：10.1021/ol502551u

  日期：2014.10.3

  A highly stereoselective one-pot procedure for the synthesis of five-membered annulated hydroxycoumarins has been developed. By merging primary amine catalysis with silver catalysis, a series of functionalized coumarin derivatives were obtained in good yields (up to 91%) and good to excellent enantioselectivities (up to 99% ee) via a Michael addition/hydroalkoxylation reaction. Depending on the substituents on the enynone, the synthesis of annulated six-membered rings is also feasible.
• TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS
  申请人：CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

  公开号：US20220119376A1

  公开（公告）日：2022-04-21

  The present invention discloses a series of tricyclic compounds and use thereof in preparing a medicament for treating a disease related to CRBN protein. Specifically, the present invention discloses a derivative compound of formula (I) or a pharmaceutically acceptable salt thereof.
• [EN] siRNA DELIVERY VECTOR<br/>[FR] VECTEUR D'ADMINISTRATION DE PARNI
  申请人：[en]COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH

  公开号：WO2022254405A1

  公开（公告）日：2022-12-08

  There is provided a complex of a 6,7-dihydroxy coumarin phosphonium amphiphile together with a negatively charged agent. The complex self-assembles into a nanoparticle or non-viral vector for facilitating delivery of the negatively charged agent. The negatively charged agent may be a therapeutic agent or a diagnostic agent. Thus, the present invention provides a method of delivery of such negatively charged agents to a target cell, and in particular facilitates delivery of a therapeutic or diagnostic agent across the plasma membrane, as well as a method of treatment or diagnosis via delivery of the therapeutic or diagnostic agent. The 6,7-dihydroxy coumarin phosphonium amphiphile can be Mito-Esc and the negatively charged agent can be a nucleic acid such as siRNA. Additionally, the 6,7-dihydroxy coumarin phosphonium amphiphile is believed to be effective in the treatment of cancer.